Fibroblast growth factor receptor 2 (FGFR2) messenger RNA (FGFR2 mRNA)

Fibroblast growth factor receptor 2 (FGFR2) messenger RNA (mRNA) is the transcript of the FGFR2 gene, which encodes a receptor tyrosine kinase involved in critical cellular processes such as cell proliferation, survival, and embryonic development (NCBI Gene ID: 2263). The mRNA undergoes complex alternative splicing to produce tissue-specific isoforms, notably FGFR2b and FGFR2c, which are essential for epithelial-mesenchymal signaling (UniProt P21802). Dysregulation of FGFR2 mRNA, often through gene amplification, overexpression, or oncogenic fusions (e.g., FGFR2-BICC1), is a primary driver in several malignancies, including intrahepatic cholangiocarcinoma and gastric cancer (PubMed: 33073213). While most clinically approved drugs like pemigatinib and futibatinib target the resulting FGFR2 protein, the mRNA itself is an emerging therapeutic target for RNA-based modalities such as small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) (PubMed: 31558498). These RNA-targeted approaches aim to silence oncogenic signaling at the pre-translational level, potentially bypassing resistance mechanisms found in the protein's kinase domain. Beyond oncology, mutations in the FGFR2 gene and its transcript are linked to developmental disorders, including Apert and Crouzon syndromes (StatPearls: NBK538247). Monitoring FGFR2 mRNA levels and specific variants serves as a crucial biomarker for patient selection and treatment monitoring in precision medicine. Therapeutic challenges include managing class-effect toxicities like hyperphosphatemia and ensuring the high specificity required for RNA-targeting agents to avoid off-target effects.

Other names

BEK mRNAKGFR mRNAK-SAM mRNACD332 mRNAFibroblast growth factor receptor 2 transcript

RNA interference, antisense inhibition, and tyrosine kinase inhibition of the encoded protein